[951] Urinary Met Level as a Novel Biomarker for Urothelial Carcinoma of the Bladder.

Maximiliano Sorbellini, Brian McNeal, Gagani Athauda, Benjamin Cohen, Alessio Giubellino, Haley Simpson, Jonathan Coleman, Robert H Getzenberg, George J Netto, Marston W Linehan, Peter A Pinto, Donald P Bottaro. National Cancer Institute, Bethesda, MD; Memorial Sloan Kettering Cancer Center, New York, NY; Johns Hopkins University, Baltimore, MD

Background: Urothelial carcinoma (UrCa) of the bladder continues to be a major cause of mortality and morbidity in the US. Non invasive molecular markers that can improve upon current approaches for detection and surveillance are crucially needed. This study aims to determine whether soluble urinary Met (sMet) can differentiate between benign urinary bladder conditions and urinary bladder cancer. Correlation of sMet levels with UrCa tumor grade and stage is also assessed.
Design: Urinary samples from patients with and without UrCa from three different institutions were prospectively collected prior to cystosopy, transurethral resection of bladder tumor (TURBT) or cystectomy. sMet levels were determined using electrochemiluminescence immunoassays. sMet levels were normalized to urinary creatinine values. Normalized Met values were compared to final pathologic stage and grade. AUC values were obtained comparing patients with and without UrCa.
Results: Urinary sMet levels accurately differentiated between patients with and without UrCa (AUC: 78%, sensitivity, specificity and negative predictive value were: 68%, 78% and 95%, respectively), patients with no UrCa and those with lamina propria invasion (AUC: 79%, sensitivity, specificity and negative predictive value were: 65%, 81% and 95%, respectively) and patients with no UrCa and those with muscle invasive disease (AUC: 85%, sensitivity, specificity and negative predictive value were: 75%, 83% and 97%, respectively).
Conclusions: Urinary sMet level may provide a new biomarker for UrCa of the bladder. sMet levels accurately distinguish patients with UrCa from those without, and between patients with different tumor stages. These results suggest that urinary sMet may have utility as a bladder cancer marker for screening, treatment follow-up and clinical trial design.
Category: Genitourinary (including renal tumors)

Tuesday, March 1, 2011 9:30 AM

Poster Session III # 185, Tuesday Morning


Close Window